IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.
The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma|Nasopharyngeal Neoplasms|Nasopharyngeal Diseases|Head and Neck Neoplasm
DRUG: Tolipalimab|RADIATION: Reirradiation
ORR, Objective Response Rate, Through study completion, an average of 1 year
PFS, Progression-Free Survival is defined as time interval from recruitment to tumor progression or censoring., up to 3 years|OS, Overall Survival is defined as time interval from recruitment to all-caused death or censoring., up to 3 years|Incidence of Treatment-Emergent Adverse Events, Adverse events (AE), Serious Adverse Event(SAE), Through study completion, an average of half a year
This is an open-label ,single center ,non-randomized, single arm exploratory study. All eligible patients presented with non-keratinizing NPC and stage rT0-4N1-3M0 /rT2-4N0M0 are assigned to receive IMRT combined with toripalimab.